Please login to the form below

Not currently logged in
Email:
Password:

clinical benefit

This page shows the latest clinical benefit news and features for those working in and with pharma, biotech and healthcare.

FDA sets Q3 decision date for NS Pharma’s DMD drug

FDA sets Q3 decision date for NS Pharma’s DMD drug

a “reasonably likely” clinical benefit.

Latest news

More from news
Approximately 1 fully matching, plus 156 partially matching documents found.

Latest Intelligence

  • Alzheimer’s: the search for a cure Alzheimer’s: the search for a cure

    The analysis of the expanded data set for one of the phase 3 trials, EMERGE, linked aducanumab to improvements on a clinical dementia scale. ... The preponderance of the data indicates aducanumab doesn’t provide a clinical benefit,’ Skorney wrote in

  • Novel endpoints in the digital age Novel endpoints in the digital age

    Every clinical trial has an endpoint, a measure used to determine if the drug in question provides therapeutic benefit. ... measure safety, efficacy and clinical benefit of a medicine in a trial.

  • The European Medicines Agency: PRIME’d for access? The European Medicines Agency: PRIME’d for access?

    The scheme. The PRIME scheme is for medicines that have real promise, defined by the EMA as medicines that may offer a major therapeutic advantage over existing treatments, or benefit patients ... Companies who want to benefit from the scheme have to

  • Can new data aggregators shift the balance of power away from pharma? Can new data aggregators shift the balance of power away from pharma?

    This could have far-reaching consequences for some players in the pharmaceutical industry who may find their product pricing to be untenable when the cost/clinical benefit calculus becomes totally transparent.

  • Patient recruitment and engagement standards Patient recruitment and engagement standards

    And the reality: 50% of clinical research sites don’t recruit a single patient. ... A number of studies have revealed that awareness changes patients’ perceptions about clinical trials, enrolment and the risk/benefit ratio of getting involved.

More from intelligence
Approximately 0 fully matching, plus 25 partially matching documents found.

Latest appointments

  • Dr Irina Antonijevic joins vasopharm Dr Irina Antonijevic joins vasopharm

    In this role, Dr Antonijevic will be responsible for advancing the clinical development of the cerebrovascular specialist's lead orphan drug candidate, VAS203. ... Not only will we benefit from her clinical capabilities in our ongoing pivotal study of

  • ICON's CEO named chair of ACRO ICON's CEO named chair of ACRO

    Trade body for clinical research organisation elects Ciaran Murray. The global trade body for clinical research organisations has elected ICON's CEO Ciaran Murray as chairman. ... I look forward to continuing the work that ACRO has done in promoting our

  • Industry veteran Louis Nisbet joins Sygnature board Industry veteran Louis Nisbet joins Sygnature board

    The UK-based clinical research organisation (CRO) will benefit from Dr Nisbet's extensive experience in the life sciences industry, which includes spells in research at Roche, Glaxo and SmithKline.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 16 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics